To clarify the impact of mild post-procedural aortic regurgitation (post-AR) on clinical outcomes.
The Edwards valve was the most frequently used in group 1 compared to group 2 and 3 (89.3, 78.7 and 83.3%, p=0.03 ) and the implanted valve size was similar in all groups (25.6±2.0, 25.4±2.2 and 25.5±2.2 mm respectively, p=0.69). Post-dilatation was required more frequently in group 3 (4.7, 24.1 and 50.0% respectively, p<0.01). Post-procedural increase in mitral regurgitation was in line with the post-AR grade (0.78±0.73, 1.22±0.80 and 1.89±0.78, respectively, p<0.01).
Despite the absence of difference in 30-day mortality, longer-term outcome showed patients with mild AR had a significantly worse outcome compared to none (log-rank p<0.01) and better than moderate to severe (p=0.04), regardless of TAVI type and left ventricular function.
Post-AR was also identified as an independent predictor for mid-long term mortality (HR1.68, 95%CI:1.21-1.44, p<0.01).
Conclusion:
Mild post-AR after TAVI is associated with worse outcome compared to none to trivial. Cautious valve selection and post-dilatation when required to avoid mild post-AR might contribute to improved clinical outcome after TAVI. Background and objective: Bleeding post-PCI is associated with increased in-hospital mortality and adverse outcomes. Data regarding the determinants and outcomes of bleeding after transcatheter aortic valve implantation (TAVI) are limited. We assessed the incidence, predictors and clinical impact of bleeding after TAVI in patients from a single center registry.
Methods:
We included 250 consecutive patients implanted in our center between May 2006 and October 2011. All procedures were performed using the balloon expandable Edwards SAPIEN and SAPIEN XT valves, via transfemoral (TF) and transapical (TA) approach. Introducers of 22 and 24 F or surgical cutdown were used for TF access when implanting the SAPIEN valve, while SAPIEN XT valve was implanted using 18 and 19F sheaths and percutaneous closure. The Ascendra 1, 28F and 2, 26F systems were used for TA access. Dual antiplatelet therapy was administered preprocedurally in TF cases, aspirin only in TA cases, with 70 UI/kg of unfractionated heparin after sheath insertion. Life-threatening (LTB), major, minor bleeding and other complications were defined using VARC criteria.
Results: TAVI was performed via TF access in 190 (76%) cases, and the SAPIEN XT model was used in 123 (49.2%) cases. Bleeding after TAVI was observed in 68 (27.2%) patients as follows: LTB in 33 (13.2%), major bleeding in 23 (9.2%) and minor bleeding in 12 (4.8%). After multivariate analysis, only TA access was an independent predictor of LTB (OR 3.35, 95% CI: 1.52 -7.38, p<0.003). Patients presenting LTB post-TAVI had a higher 30-day mortality: 33.3% vs. 3.7%, p<0.001 and 1-year mortality: 46% vs. 82%, p<0.001. LTB was an independent predictive factor for 30-day (OR 6.98, 95% CI: 1.93 -25.1, p=0.003) and 1-year mortality (HR 2.18, 95% CI: 1.11 -4.28, p=0.024).
Conclusion:
Bleeding represents a frequent complication of TAVI, being observed in over 25% of cases in this single center registry. It is associated with higher 30-day and 1 year mortality.
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Four-year durability of aortic valve bioprosthesis after transcatheter implantation: an echocardiographic prospective study Background: Transcatheter aortic valve implantation (TAVI) has become a recognized alternative to conventional surgery in high-risk patients with severe symptomatic aortic stenosis. However, little is known about the longterm durability of the prosthesis as assessed by periodic transthoracic echocardiography (TTE). We aim to evaluate aortic valve hemodynamics by TTE performed after TAVI using Edwards Sapien/Sapien XT bioprosthesis.
Methods: All consecutive patients implanted between March 2005
and January 2012 were included in a prospective registry. TTE data were collected before TAVI, within 7 days, at 6 months and yearly after the procedure. Doppler interrogation was used for peak, mean pressure gradient and effective orifice area (EOA) using the continuity equation. Aortic regurgitation (AR) and ejection fraction (EF) were assessed.
Results: Two hundred and sixty one patients underwent successful TAVI implantation and were included in the registry (table) . Left ventricular ejection fraction (LVEF) was improved early after TAVI procedure. Both Peak and mean pressure gradient significantly decreased after TAVI while EOA increased. No aortic regurgitation >grade 2 was found 3 and 4 years after TAVI. Four-year TTE follow-up did not demonstrate any significant change in peak pressure gradient, mean pressure gradient, EOA or occurrence of severe aortic regurgitation compared to 7-day post-operative. All parameters except LVEF remained significantly improved at 4-year compared to pre-TAVI examination.
Conclusion:
Our study demonstrates the excellent hemodynamic performance of the Edwards Sapien/Sapien XT aortic bioprosthesis 4-year after transcatheter implantation offering promising information on valve durability. 
